SG11201909022PA - ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF - Google Patents

ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Info

Publication number
SG11201909022PA
SG11201909022PA SG11201909022PA SG11201909022PA SG 11201909022P A SG11201909022P A SG 11201909022PA SG 11201909022P A SG11201909022P A SG 11201909022PA SG 11201909022P A SG11201909022P A SG 11201909022PA
Authority
SG
Singapore
Prior art keywords
international
indianapolis
n3pglu
antibodies
company
Prior art date
Application number
Inventor
Ronald Bradley Demattos
Jirong Lu
Ying Tang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11201909022PA publication Critical patent/SG11201909022PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIP0 I PCT 0111111010 0111 °nolo ommoimin minio oimIE (10) International Publication Number WO 2018/194951 Al (51) International Patent Classification: C07K 16/18 (2006.01) A61K 39/00 (2006.01) A61P 25/28 (2006.01) (21) International Application Number: PCT/US2018/027718 (22) International Filing Date: 16 April 2018 (16.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/487,550 20 April 2017 (20.04.2017) US (71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US). (72) Inventors: DEMATTOS, Ronald Bradley; c/o ELI LIL- LY AND COMPANY, P.O. Box 6288, Indianapolis, In- diana 46206-6288 (US). LU, Jirong; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indi- ana 46206-6288 (US). TANG, Ying; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). (74) Agent: THOBE, Megan N. et al.; ELI LILLY AND COM- PANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 1-1 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). 1-1 1 1 Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF 0 (57) : Antibodies to human N3pGlu Af3, compositions comprising such N3pGlu Af3 antibodies, and methods of using such \" N3pGlu Af3 antibodies for the treatment of a disease characterized by deposition of Af3 including clinical or pre-clinical Alzheimers C disease, Downs syndrome, and clinical or pre-clinical cerebral amyloid angiopathy.
SG11201909022P 2017-04-20 2018-04-16 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF SG11201909022PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762487550P 2017-04-20 2017-04-20
PCT/US2018/027718 WO2018194951A1 (en) 2017-04-20 2018-04-16 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
SG11201909022PA true SG11201909022PA (en) 2019-11-28

Family

ID=62111232

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909022P SG11201909022PA (en) 2017-04-20 2018-04-16 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Country Status (28)

Country Link
US (3) US10647759B2 (en)
EP (1) EP3612559A1 (en)
JP (3) JP6900500B2 (en)
KR (2) KR102352670B1 (en)
CN (2) CN110582511B (en)
AR (1) AR111208A1 (en)
AU (2) AU2018255221B2 (en)
BR (1) BR112019018810A2 (en)
CA (1) CA3058482C (en)
CL (1) CL2019002922A1 (en)
CO (1) CO2019011349A2 (en)
CR (1) CR20190445A (en)
DO (1) DOP2019000241A (en)
EA (1) EA201992163A1 (en)
EC (1) ECSP19075146A (en)
IL (1) IL269003A (en)
JO (1) JOP20190247A1 (en)
MA (1) MA50144A (en)
MX (2) MX2019012445A (en)
NZ (1) NZ758066A (en)
PE (1) PE20200011A1 (en)
PH (1) PH12019502361A1 (en)
SA (1) SA519410311B1 (en)
SG (1) SG11201909022PA (en)
TW (2) TWI789644B (en)
UA (1) UA126806C2 (en)
WO (1) WO2018194951A1 (en)
ZA (1) ZA202007868B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (en) 2016-11-03 2018-08-01 比利時商健生藥品公司 Antibodies to pyroglutamate amyloid-[beta] and uses thereof
KR20210143858A (en) 2019-03-26 2021-11-29 얀센 파마슈티카 엔.브이. Antibodies against pyroglutamate amyloid-β and uses thereof
WO2021151011A2 (en) * 2020-01-24 2021-07-29 The Board Of Trustees Of Western Michigan University Treatment of neurodegenerative proteinopathies using fas apoptosis inhibitory molecule (faim) or a fragment and/or a mimetic thereof
CA3192910A1 (en) 2020-10-02 2022-04-07 Brian David BOWES Methods for reducing host cell protein content in protein purification processes
TW202243690A (en) 2021-01-11 2022-11-16 美商美國禮來大藥廠 Anti-n3pglu amyloid beta antibodies and uses thereof
TW202300518A (en) 2021-03-12 2023-01-01 美商美國禮來大藥廠 Anti-n3pglu amyloid beta antibodies and uses thereof
TW202300517A (en) 2021-03-12 2023-01-01 美商美國禮來大藥廠 Anti-amyloid beta antibodies and uses thereof
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
JP7268910B2 (en) * 2021-09-16 2023-05-08 株式会社ユニバーサルエンターテインメント game machine
JP7306746B2 (en) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント game machine
JP7306745B2 (en) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント game machine
WO2023070064A1 (en) * 2021-10-22 2023-04-27 Eli Lilly And Company O-glcnacase (oga) inhibitor combination therapy
WO2023076995A1 (en) * 2021-10-29 2023-05-04 Eli Lilly And Company Compounds and methods targeting interleukin-34
WO2023076971A1 (en) 2021-10-29 2023-05-04 Eli Lilly Company Compounds and methods targeting interleukin-34
TW202334210A (en) 2021-10-29 2023-09-01 美商美國禮來大藥廠 Compounds and methods targeting interleukin-34
WO2023076970A1 (en) * 2021-10-29 2023-05-04 Eli Lilly And Company Compounds and methods targeting interleukin-34
WO2023150483A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease
CN117327168A (en) * 2022-06-24 2024-01-02 厦门大学 B2M-GluN1 blocking peptide, pharmaceutical composition and application thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100767146B1 (en) * 2000-02-24 2007-10-15 워싱톤 유니버시티 Humanized Antibodies That Sequester Amyloid Beta Peptide
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
JP2006513259A (en) 2002-07-24 2006-04-20 イノジェネティックス・ナムローゼ・フェンノートシャップ Prevention, treatment and diagnosis of diseases associated with beta-amyloid production and / or aggregation
WO2005025616A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
CA2575663C (en) 2004-07-30 2013-04-23 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
MY148086A (en) * 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
CA2657681C (en) 2006-07-14 2019-03-19 Ac Immune S.A. Humanized antibodies against beta amyloid protein
RU2011100127A (en) 2008-06-12 2012-07-20 Аффирис Аг (At) COMPOUND CONTAINING A PEPTIDE FOR TREATING SYMPTOMS OF PARKINSON'S DISEASE
WO2010004434A2 (en) 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
MX2011000875A (en) 2008-07-21 2011-04-05 Probiodrug Ag Diagnostic antibody assay.
WO2011151076A2 (en) 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
WO2012021475A2 (en) 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
AU2011289629B2 (en) * 2010-08-12 2014-07-03 Eli Lilly And Company Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
WO2015175769A1 (en) * 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
TWI599358B (en) 2014-09-16 2017-09-21 美國禮來大藥廠 Combination therapy
DK3283106T3 (en) * 2015-04-13 2022-01-10 Pfizer Therapeutic antibodies and uses thereof
JOP20170004B1 (en) * 2016-01-15 2022-09-15 Lilly Co Eli ANTl-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
TWI798751B (en) * 2016-07-01 2023-04-11 美商美國禮來大藥廠 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
WO2018194951A1 (en) 2018-10-25
TWI789644B (en) 2023-01-11
AU2018255221A1 (en) 2019-09-19
AU2018255221B2 (en) 2021-07-01
US20210371509A1 (en) 2021-12-02
AU2021203927A1 (en) 2021-07-08
SA519410311B1 (en) 2022-03-20
BR112019018810A2 (en) 2020-05-05
TWI705975B (en) 2020-10-01
CL2019002922A1 (en) 2020-03-13
US11078261B2 (en) 2021-08-03
ZA202007868B (en) 2023-06-28
JP2021151253A (en) 2021-09-30
KR102567295B1 (en) 2023-08-16
JP6900500B2 (en) 2021-07-07
DOP2019000241A (en) 2019-10-15
UA126806C2 (en) 2023-02-08
TW201902924A (en) 2019-01-16
EA201992163A1 (en) 2020-03-02
TW202120541A (en) 2021-06-01
JP7227312B2 (en) 2023-02-21
PE20200011A1 (en) 2020-01-06
CA3058482A1 (en) 2018-10-25
KR20190129100A (en) 2019-11-19
US20200262902A1 (en) 2020-08-20
CR20190445A (en) 2019-11-06
NZ758066A (en) 2022-10-28
JP2023058623A (en) 2023-04-25
CA3058482C (en) 2023-05-09
JP2020510081A (en) 2020-04-02
MX2019012445A (en) 2020-01-13
MA50144A (en) 2020-07-29
JOP20190247A1 (en) 2019-10-20
US20180305444A1 (en) 2018-10-25
AR111208A1 (en) 2019-06-12
KR20220011800A (en) 2022-01-28
ECSP19075146A (en) 2019-10-31
IL269003A (en) 2019-10-31
PH12019502361A1 (en) 2020-07-13
MX2022011817A (en) 2022-10-10
US10647759B2 (en) 2020-05-12
CN117024583A (en) 2023-11-10
EP3612559A1 (en) 2020-02-26
AU2021203927B2 (en) 2024-03-21
CO2019011349A2 (en) 2019-10-31
CN110582511B (en) 2023-08-08
CN110582511A (en) 2019-12-17
KR102352670B1 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201810371XA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201900844UA (en) Amino pyrimidine ssao inhibitors
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201907032RA (en) Amino pyrimidine compounds useful as ssao inhibitors
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201908540PA (en) Stable antibody formulation
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201408261UA (en) Syringe
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201901673SA (en) Imidazole derivatives and their use in the treatment of autoimmune or inflammatory diseases or cancers
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201808882QA (en) Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201407345QA (en) Pyrazole compounds as sglt1 inhibitors
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer